Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline dose optimization in preterm neonatal sepsis
NL-OMON49542Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pentoxifylline in late-onset neonatal sepsis (LONS) and bloodstream infection (BSI), sponsored by Erasmus MC. Primary endpoint: Dose optimization based on clinical and biochemical response and adverse effects. Started Jan 2020; status: completed.
02
Drugs
pentoxifylline
03
Conditions
late-onset neonatal sepsis (LONS)bloodstream infection (BSI)
Beyond the preview
Go deeper on NL-OMON49542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49542.